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Pulmonary hypertension often has a lethal outcome in systemic sclerosis and the treatment is challenging. 
Epoprostenol is a potent pulmonary vasodilator and its efficacy has been demonstrated when delivered by the 
intravenous and aerosolized routes. We report the haemodynamic and functional benefits of epoprostenol 
administered by inhalation to a spontaneously breathing patient with partially reversible pulmonary hypertension 
due to systemic sclerosis. Aerosolized epoprostenol, equivalent to the maximum tolerated intravenous dose 
(31,2yg), produced a 58% fall in pulmonary vascular resistance, increased the cardiac output by 42% and improved 
functional performance by one MET (3.5 ml kg - ’ min ~ ’ of oxygen uptake) without any significant side-effects. 
Selective distribution of epoprostenol by the inhaled route may offer a new strategy for treatment of pulmonary 
hypertension. 
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Introduction 
Pulmonary hypertension has been observed in 55-80% of 
patients with systemic sclerosis (1) either with or without 
associated parenchymal and interstitial involvement. While 
there is no cure for pulmonary hypertension associated with 
systemic sclerosis and other connective tissue diseases, 
several pharmacological (2) and surgical (3) approaches to 
treatment have been developed over the last decade which 
have proved beneficial in a significant proportion of 
patients. In particular, vasodilator therapy may produce 
sustained haemodynamic and symptomatic improvement in 
up to approximately two-thirds of patients. The most 
promising results have been obtained with intravenous 
administration of epoprostenol (3-5) and a synthetic ana- 
logue, Iloprost (6). Intravenous epoprostenol (prostacyclin) 
has been administered acutely to assess reversibility in 
pulmonary artery pressures (7) and chronically for the 
treatment of pulmonary hypertension (3-5), but its admin- 
istration is often associated with significant systemic 
side-effects. 
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Selective distribution via the inhaled route would target 
the pulmonary circulation (8) thereby reducing systemic 
side-effects and obviating the need for indwelling intra- 
venous catheters. Nitric oxide has been shown to be an 
effective and safe vasodilator with acute improvement in 
pulmonary haemodynamics in patients with pulmonary 
hypertension (7,9) and chronic improvement in exercise 
capacity in patients with severe heart failure and right 
ventricular dysfunction (10). There is less information on 
the haemodynamic and functional effects of aerosolized 
prostacyclin (11-13). The safety and efficacy of nebulised 
epoprostenol (Flolan, Wellcome Laboratories, Beckenham, 
Kent, U.K.) has already been demonstrated in ventilated 
patients with adult respiratory distress syndrome (14) and 
in patients with severe pulmonary hypertension (15). 
We report both haemodynamic and functional benefits of 
epoprostenol delivered by inhalation to a spontaneously 
breathing patient with pulmonary hypertension due to 
systemic sclerosis. 
Case Report 
A 53-year-old Nigerian woman presented in 1991 with an 
illness clinically and immunologically suggestive of mixed 
connective tissue disease associated with exertional dysp- 
noea. Initial investigations showed a normochromic, nor- 
mocytic anaemia, ESR of 30 mm, leukopenia, positive 
nucleolar pattern of staining for anti-nuclear factor in a 
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TABLE 1. The effect of nebulised epoprostenol on pulmonary vascular haemodynamics, FEV, and systemic blood pressure 
in a patient with systemic sclerosis 
Dose 
Mean Mean Mean CI PVR SVR 
RAP PAP PAWP HR SBP (1 min-’ FEV, SaO, (dyne s - ’ cm ~ ‘) (dyne s ~ i cm - “) 
(mm Hg) (mm Hg) (mm Hg) (bpm) (mean) m -“) (litres) (%) (% reduction) (% reduction) 
Control 
(diluent) 
5OPug 
lOOPug 
200 iug 
4OO.a 
15 16174 10 88 129177 2.69 1.3 90 1400 (0%) 2288 (0%) 
(57) (92) 
11 58127 12 60 134172 3.88 1.25 92 597.6 (57%) 1712 (25%) 
(41) (94) 
8 57124 12 69 127170 3.53 93 521.6 (63%) 1832(20%) 
(35) (89) 
8 54121 12 71 126164 3.57 1.20 99 649.6 (54%) 1728 (24%) 
(41) (85) 
9 57/28 10 73 126165 3.81 1.10 99 588(58%) 1616 (29%) 
(38) (86) 
RAP: right atria1 pressure, PAP: pulmonary artery pressure, PAWP: pulmonary artery wedge pressure, HR: heart rate, SBP: 
systemic blood pressure, CI: cardiac index, PVR: pulmonary vascular resistance, SVR: systemic vascular resistance. 
titre of l/5000 and negative rheumatoid factor, d-DNA, 
ANCA and cardiolipin, with normal complement levels. 
Antibodies to RNP, Scl-70 and centromere were also 
negative. Anti-R0 antibody was weakly positive. Her 
clinical condition evolved into systemic sclerosis (ARA 
criteria) (16) with Raynaud’s phenomenon, vitiligo, diffuse 
skin thickening and digital ulcers. 
In October 1994 she developed right-sided heart failure. 
She was treated with frusemide 40 mg, nifedepine 5 mg 
twice daily and prednisolone 10 mg once daily. An invasive 
haemodynamic study was performed using a triple lumen 
thermodilution Swan-Ganz catheter to record the following 
pressures (systolic/diastolic, mean) (mm Hg): right atria1 
pressure (RAP 12/2, 8; pulmonary arterial pressure (PAP) 
66/36, 46; femoral arterial pressure (FAP) 126165, 86; mean 
pulmonary artery wedge pressure (PAWP) 10, cardiac index 
(CI) 2.9 1 min- ’ m-‘. Pulmonary vascular resistance 
(PVR) was calculated to be 992 dyne s ~ ’ cm - 5 and 
fell by 53% with intravenous sodium nitroprusside 
(2.5 ng kg - i min - ‘). Intravenous epoprostenol lowered 
PVR in a dose-dependent manner, by 39% at 4, 48% at 8 
and 57% at 12 ng kg - ’ min ~ i (representing a total dose of 
31.2pg). The beneficial effect of sodium nitroprusside was 
accompanied by a symptomatic fall in FAP (to 89/45, 58) 
whereas epoprostenol only caused a 13% fall in mean FAP, 
but there was unpleasant flushing, nausea, and abdominal 
cramps at doses of 8 and 12 ng kg - ’ min - I. 
The patient was then commenced on nifedepine 40 mg 
four times a day for 2 months and then the dose was 
reduced to 10 mg four times a day. Subsequently, in June 
1995, the efficacy of epoprostenol made up in a vehicle of 
2 ml of 0.188% glycink and 0.147% NaCl (pH 10.5) and 
delivered by a jet nebuliser was studied. Baseline haemo- 
dynamics were measured as before and demonstrated a 15% 
rise in systolic PAP, a 9% rise in mean PAP and a 41% rise 
in PVR compared with the previous study. We used a 
Wright’s nebuliser (Aerosol Products Ltd., London, U.K.) 
driven by a compressor at a calibrated flow rate of 
7lmin-’ and 17 psi to deliver the aerosols via a face mask 
during tidal breathing. The output of the nebuliser was 
checked by the conventional weight loss method and the 
concomitant loss of solute by evaporation during the 
nebulisation was measured by using a fluoride tracer 
and aerosol impaction method (17). The nebuliser gave 
an output of 120-150~1 min ~ I, of which 67% was lost 
by evaporation. The effective nebulised dose was 
40-50 ~1 min ~ ’ (33%). The respiratory pattern during tidal 
breathing was monitored using a spirogram and the 
inspiratory-expiratory ratio was calculated as 1:3. The 
effective amount of the drug delivered to the airways 
was therefore about 85 (25% of 33%) of the volume 
nebulised. 
Doses were administered over 10 min and the volume of 
residue recorded. Between each administration, haemo- 
dynamic values were allowed to return to baseline. A pulse 
oximeter was used to monitor arterial oxygen saturation 
(SpO,). FEV, was measured after each nebulisation using a 
Vitalograph dry rolling spirometer. Table 1 shows the 
haemodynamic effects observed together with the changes 
in oxygen saturation. The duration of effect varied with the 
dose of epoprostenol: 19 min for 5Opg, 26 min for 100 fig, 
38 min for 2OOpg and 39 min for 4OOpg. 
The patient was subsequently exercised on a treadmill 
according to the modified Naughton protocol (18). The 
work load was quantified as metabolic equivalents (MET, 1 
MET=3.5mlkg-‘min-’ of oxygen uptake). The exercise 
started at less than 2 METS at 2 mph and zero gradient and 
increased by 1.0 to 1.5 METS between stages. The exercise 
was preceded by 2 min of warm-up and each stage lasted 
for 2 min. Systolic PAP at rest and post-exercise were 
measured from Doppler estimate of the regurgitant pres- 
sure across the tricuspid valve. At the same time the 
following day, epoprostenol (2OOpg) was nebulised over 
10 min as previously described, PAP measured and exercise 
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TABLE 2. Response to exercise at baseline and 8 min after 10 min of nebulisation of 2OOpg 
epoprostenol 
Baseline After nebulisation 
Level of exercise (mph, % gradient) 
Duration of exercise 
METS 
HR 
Systolic BP (mm Hg) 
A Systolic PAP (mm Hg) 
A SpO, (%) 
2, 14% 2, 17% 
llmin,24s 12 min, 25 s 
6 7 
147 149 
110 130 
+47 +63 
-4 -4 
was commenced 8 min after the nebulisation was complete. 
Table 2 shows the changes in exercise tolerance, heart rate, 
blood pressure and SpOz, and PAP before and after the 
nebulisation. 
higher local concentration produces longer lasting vasodi- 
lator effects. This is further exemplified by the observation 
that the oxygen saturation improved progressively through- 
out the study, exhibiting a dose-related increment which did 
not return to baseline by the time the next dose was 
administered. 
iscussion 
This case report highlights several interesting aspects of 
clinical features and treatment of pulmonary hypertension 
with systemic sclerosis. We have shown that nebulised 
epoprostenol is safe and effective in improving haemo- 
dynamics in systemic sclerosis and can be employed as 
a screening method for assessment of reversibility in 
pulmonary haemodynamics. Secondly, we have demon- 
strated that it can be delivered to spontaneously breathing 
patients, thereby making it an alternate method of long- 
term administration of this drug. Thirdly, we have demon- 
strated objectively an improvement in the functional 
performance following aerosolized administration of the 
drug. 
In summary, this case demonstrates that inhaled epo- 
prostenol delivered to a spontaneously breathing patient 
with progressive pulmonary hypertension due to systemic 
sclerosis was safe and produced clinically significant pul- 
monary vasodilatation, an improvement in effort tolerance 
and a sustained increase in arterial oxygenation presumably 
by improving V/Q mismatch. These data and the obser- 
vation that the inhaled route of administration avoided the 
side-effects associated with the intravenous use indicate that 
aerosolized epoprostenol can be safely and effectively used 
as a screening agent for assessing reversibility of pulmonary 
hypertension and that further acute and chronic studies are 
required. 
In this study, the maximum improvements in PAP and 
PVR were observed with 100 pg of nebulised epoprostenol, 
whereas the maximum improvements in CI and SpO, were 
observed with 4OOpg which was the highest dose of neb- 
ulised epoprostenol (effective airway dose of 32pg). This 
was roughly equivalent to the maximum tolerated intrave- 
nous dose (31.2 pug) and produced a 58% fall in pulmonary 
vascular resistance and increased cardiac output by 42% 
without causing any systemic symptoms, although a dose- 
dependent fall in FEV, was observed. These observations 
are comparable to previously reported results (11). In 
addition to producing acute lowering of pulmonary artery 
pressure and resistance, 200 ,ug of epoprostenol (effective 
airway dose of 16pg) caused an increase in exercise toler- 
ance by one MET, 8 min after completion of nebulisation. 
Although this is only a modest improvement in exercise 
performance and the study was not placebo-controlled, this 
observation could have important clinical implication in the 
management of pulmonary hypertension. 
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